FDA approved immune checkpoint inhibitors (ICI), blocking PD-1, PD-L1/PD-L2 or CTLA-4, have shown strong results in melanoma and Hodgkin lymphoma, but the gynecological cancers, including cervical cancer, have had significantly fewer responders to immunotherapy-only treatments; concurrent conventional fractionated radiotherapy with immunotherapy trials are currently accruing [21]. The gene discussed is CTLA4; the disease is cervical cancer.